Method for determining the methylation status of the promoter region of the TWIST1 gene in genomic DNA from bladder cells
View Patent ↗Disclosed are methods for determining the methylation status of the promoter region of the TWIST1 gene in genomic DNA from bladder cells, including bladder cells present in a urine sample. Also disclosed are kits for performing the disclosed methods, such as kits for determining the methylation status of the promoter region of the TWIST1 gene comprising at least one primer pair for determining the methylation status of TWIST1. The kits may contain means for processing a urine sample.
1. A method comprising:
(a) treating genomic DNA isolated from bladder cells in a urine sample with a reagent which selectively modifies unmethylated cytosine residues in DNA contained in the sample to produce detectable modified residues but which does not modify methylated cytosine residues;
(b) amplifying the treated genomic DNA with primers that bind to the promoter region of the TWIST1 gene to produce an amplicon; and
(c) detecting the amplicon to determine the methylation status of the promoter region of the TWIST1 gene;
wherein the amplicon is detected by contacting the amplicon with a probe, and:
(i) the probe comprises the nucleotide sequence of SEQ ID NO:24; or
(ii) the amplicon comprises the probe binding site for SEQ ID NO:24.
2. The method of claim 1 , wherein a stabilizing buffer is added to the urine sample, the stabilizing buffer permitting the urine sample to be stored for a period of up to 72 hours at room temperature without the need for centrifugation of the sample.
3. The method of claim 1 , wherein the reagent is a bisulfite reagent.
4. The method of claim 1 , wherein the treated genomic DNA is amplified with primers that bind to a methylated sequence in the promoter region of the TWIST1 gene.
5. The method of claim 1 , wherein the probe comprises the nucleotide sequence of SEQ ID NO:24.
6. The method of claim 1 , wherein the amplicon comprises the probe binding site for SEQ ID NO:24.
7. The method of claim 1 , further comprising performing urinary cytology analysis.
8. The method of claim 1 , further comprising performing mutation analysis.
9. The method of claim 8 , wherein the mutation analysis is FGFR3 gene mutation analysis.